Login to Your Account



Earnings Roundup


Tuesday, July 24, 2012
• InterMune Inc., of Brisbane, Calif., reported net second-quarter revenue of $5.5 million for Esbriet (pirfenidone) and said it reached agreement on a reimbursement price of €26,999 (US$33,000) per patient per year in Germany, a discount of about 10 percent from the current price.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription